drugset / Trial / NCT02492308
Induction With SVF Derived MSC in Living-related Kidney Transplantation
RandomizedParallel-groupOpen-labelTreatment
Summary
The objective of this trial is to determine if autologous SVF derived MSC can effectively reduce the need for post transplant immunosuppressant in living-relative kidney transplantation. 120 patients eligible for the study as described below will be enrolled, with 60 patients in intervention group and 60 in control group.
Timeline
- Start
- 2014-12
- Primary completion
- 2016-12
- Completion
- 2017-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Basiliximab | Monoclonal antibody | — | — |
Indications
No indication recorded.